SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): May 4, 2004
ARIAD PHARMACEUTICALS, INC.
---------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
-------- ------- ----------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated May 4, 2004.
This Press Release is being furnished pursuant to Item 12 of this
Current Report on Form 8-K and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934 (the
"Exchange Act") or otherwise subject to the liabilities of that
Section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act.
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On May 4, 2004, ARIAD Pharmaceuticals, Inc. announced its financial
results for the three months ended March 31, 2004. A copy of the Press
Release is furnished pursuant to this Item 12 as Exhibit 99.1 to this
Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
-------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: May 4, 2004
2
EXHIBIT INDEX
-------------
Exhibit Sequential Page
Number Description Number
- ------- ----------- ---------------
99.1 The Registrant's Press Release dated May 4, 2004. 4
3